{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:52:52Z","timestamp":1790707972898,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jhepr.2021.100392","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T22:58:32Z","timestamp":1636671512000},"page":"100392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis"],"prefix":"10.1016","volume":"4","author":[{"given":"Yi","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3092-1102","authenticated-orcid":false,"given":"Benjamin E.","family":"Decato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar D.","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9794-7596","authenticated-orcid":false,"given":"Diane E.","family":"Shevell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"McNaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petia","family":"Shipkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4839-0979","authenticated-orcid":false,"given":"Abraham","family":"Apfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giridhar S.","family":"Tirucherai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2021.100392_bib1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100392_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100392_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12072-015-9656-7","article-title":"Bile acids: emerging role in management of liver diseases","volume":"9","author":"Asgharpour","year":"2015","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2021.100392_bib4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100392_bib5","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1210\/jc.2017-01397","article-title":"Bile acid alterations are associated with insulin resistance, but not with NASH, in obese subjects","volume":"102","author":"Legry","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jhepr.2021.100392_bib6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100392_bib7","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1136\/gutjnl-2017-314307","article-title":"Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD","volume":"67","author":"Jiao","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100392_bib8","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2021.100392_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity"},{"key":"10.1016\/j.jhepr.2021.100392_bib10","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100392_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1530\/JOE-17-0727","article-title":"FGF21 acts as a negative regulator of bile acid synthesis","volume":"237","author":"Chen","year":"2018","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.jhepr.2021.100392_bib12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.bbadis.2018.05.011","article-title":"Animal models to study bile acid metabolism","volume":"1865","author":"Li","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jhepr.2021.100392_bib13","first-page":"756A","article-title":"Safety and pharmacokinetics of multiple-dose BMS-986036 in healthy Japanese and non-Japanese adults [abstract]","volume":"68","author":"Tirucherai","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100392_bib14","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/toxsci\/kfu195","article-title":"Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patients","volume":"142","author":"Woolbright","year":"2014","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jhepr.2021.100392_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nature12347","article-title":"Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome","volume":"499","author":"Yoshimoto","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jhepr.2021.100392_bib16","doi-asserted-by":"crossref","first-page":"9925","DOI":"10.18632\/oncotarget.24066","article-title":"Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice","volume":"9","author":"Yamada","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhepr.2021.100392_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0016-5085(93)90846-5","article-title":"Increased serum deoxycholic acid levels in men with colorectal adenomas","volume":"104","author":"Bayerd\u00f6rffer","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100392_bib18","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19990415)85:8<1664::AID-CNCR4>3.0.CO;2-O","article-title":"Colonic mucosal proliferation is related to serum deoxycholic acid levels","volume":"85","author":"Ochsenkuhn","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2021.100392_bib19","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100392_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100392_bib21","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100392_bib22","first-page":"757","article-title":"Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention","volume":"5","author":"Mill\u00e1n","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jhepr.2021.100392_bib23","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100392_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2016.12.016","article-title":"Chronic over-expression of fibroblast growth factor 21 increases bile acid biosynthesis by opposing FGF15\/19 action","volume":"15","author":"Zhang","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhepr.2021.100392_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007581","article-title":"Bile salt hydrolases: gatekeepers of bile acid metabolism and host-microbiome crosstalk in the gastrointestinal tract","volume":"15","author":"Foley","year":"2019","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jhepr.2021.100392_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/toxsci\/kfy271","article-title":"Pharmacological activation of PXR and CAR downregulates distinct bile acid-metabolizing intestinal bacteria and alters bile acid homeostasis","volume":"168","author":"Dempsey","year":"2019","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jhepr.2021.100392_bib27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.clnu.2019.02.037","article-title":"Unconjugated and secondary bile acid profiles in response to higher-fat, lower-carbohydrate diet and associated with related gut microbiota: a 6-month randomized controlled-feeding trial","volume":"39","author":"Wan","year":"2019","journal-title":"Clin Nutr"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921001683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921001683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:27:01Z","timestamp":1762900021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555921001683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2589555921001683"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100392","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100392"}}